Danazol therapy for aplastic anemia refractory to immunosuppressive therapy

American Journal of Hematology

Volumn 83, Issue 5, 2008, Pages 387-389

  Chuhjo, Tatsuya ^a   Yamazaki, Hirohito ^b   Omine, Mitsuhiro ^c   Nakao, Shinji ^a,b  

^a NTT CORPORATION   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL;

ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA, APLASTIC; BLOOD TRANSFUSION; COMBINED MODALITY THERAPY; DANAZOL; DRUG RESISTANCE; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HEPATITIS, TOXIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 42949139242     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21118     Document Type: Article

References (19)

1. Madanes AE, Farber M. Danazol. Ann Intern Med 1982;141:453-463.
2. Beutler B, Krochin N, Milsark W, et al. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 1986;232: 977-980.
3. Kern JA, Lamb RJ, Reed JC, et al. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. J Clin Invest 1988;81:237-244.
4. Mori H, Nakagawa M, Itoh N, et al. Danazol suppresses the production of interleukin-1 beta and tumor necrosis factor by human monocytes. Am J Reprod Immunol 1990;24:45-50.
5. Ahn YS, Harrington WJ, Simon SR, et al. Danazol for treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983;308:1396-1399.
6. Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol 1990; 84:122-129.
7. Ahn YS, Harrington WJ, Mylvaganam R, et al. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 1985;102:298-301.
8. Ahn YS, Rocha R, Harrington WJ. Long-term danazol therapy in autoimmune thrombocytopenia (abstract). Blood 1989;74:110.
9. Cervera H, Jara LJ, Pizarro S, et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. J Rheumatol 1995;22:1867-1871.
10. Lippman SM, Durie BGM, Garewal HS, et al. Efficacy of danazol in pure red cell aplasia. Am J Hematol 1986;23:373-379.
11. Najean Y, Pecking A, Danvic ML. Androgen therapy of aplastic anaemia - A prospective study of 352 cases. Scand J Haematol 1979;22:343-356.
12. Najean Y. Long-term follow-up in patients with aplastic anemia, a study of 137 androgen-treated patients surviving more than two years. Am J Med 1981;71:543-551.
13. Bacigalupo A, Chaple M, Hows J, et al. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA working party. Br J Haematol 1993;83:145-151.
14. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59 blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006;107:1308-1314.
15. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257-4261.
16. Buzaid AC, Garewal HS, Lippman SM, et al. Danazol in the treatment of myelodysplastic syndromes. Eur J Haematol 1987;39:346-348.
17. Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndromes. Br J Haematol 1991;77:502-508.
18. Chan G, DiVenuti G, Miller K. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. Am J Hematol 2002;71:166-171.
19. Camitta BM. What is the definition of cure for aplastic anemia? Acta Haematol 2000;103:16-18.